A Review of the Use of Native and Engineered Probiotics for Colorectal Cancer Therapy

Huawen Han,Yifan Zhang,Haibo Tang,Tuoyu Zhou,Aman Khan
DOI: https://doi.org/10.3390/ijms25073896
IF: 5.6
2024-04-01
International Journal of Molecular Sciences
Abstract:Colorectal cancer (CRC) is a serious global health concern, and researchers have been investigating different strategies to prevent, treat, or support conventional therapies for CRC. This review article comprehensively covers CRC therapy involving wild-type bacteria, including probiotics and oncolytic bacteria as well as genetically modified bacteria. Given the close relationship between CRC and the gut microbiota, it is crucial to compile and present a comprehensive overview of bacterial therapies used in the context of colorectal cancer. It is evident that the use of native and engineered probiotics for colorectal cancer therapy necessitates research focused on enhancing the therapeutic properties of probiotic strains.. Genetically engineered probiotics might be designed to produce particular molecules or to target cancer cells more effectively and cure CRC patients.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?
The paper primarily explores the application of native (wild-type) and genetically engineered probiotics in the treatment of colorectal cancer (CRC). Specifically, the paper addresses the following key issues: 1. **Using Native Probiotics to Treat CRC**: - **Resisting Pathogen Colonization**: Reducing pathogen colonization by restoring gut microbial balance, such as by inhibiting pathogen growth or directly killing pathogens. - **Mucosal Immune Regulation**: Regulating intestinal inflammatory responses to reduce the secretion of inflammatory cytokines, thereby alleviating inflammation and the development of CRC. - **Improving Intestinal Barrier Function**: Enhancing the expression of tight junction proteins and promoting mucus secretion to strengthen the intestinal barrier and prevent pathogen invasion. 2. **Effectiveness of Probiotics in Clinical Studies**: Through retrospective analysis of multiple clinical trial results, demonstrating the potential role of probiotics in preventing the occurrence and development of CRC, as well as their ability to alleviate side effects in CRC patients post-surgery. 3. **Genetically Engineered Bacteria for CRC Treatment**: - **Delivering Therapeutic Proteins**: Using engineered bacteria to deliver cytotoxic proteins (such as ClyA), immunomodulatory factors, etc., which can directly kill tumor cells or modulate the immune system to fight cancer. - **Delivering Prodrug-Converting Enzymes**: Utilizing engineered bacteria to convert non-toxic prodrugs into cytotoxic drugs, such as using bacterial-derived cytosine deaminase (CD) to convert 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU). In summary, this review paper aims to provide a comprehensive overview of the research progress on using native and genetically engineered probiotics for CRC treatment, and discusses the potential advantages, challenges, and future development directions of these approaches.